Basis of Presentation and Significant Accounting Policies - Collaborative Agreements (Details) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
|
| Collaborative Agreements | ||||
| Research and Development Expense | $ 809 | $ 430 | $ 1,867 | $ 530 |
| Beneficial Reuse Strategic Agreement | ||||
| Collaborative Agreements | ||||
| Research and Development Expense | 1,800 | 3,900 | ||
| Reimbursement of shared costs | 1,400 | 2,900 | ||
| Receivables due from alliance members | $ 1,500 | $ 1,500 | ||
| X | ||||||||||
- Definition The aggregate costs reimbursed for research and development costs incurred from collaborative agreements. No definition available.
|
| X | ||||||||||
- Definition Amounts receivable from members associated with collaborative agreement at the end of the period. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|